A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Have Trusted Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 358
Comprehensive Pages
- 35
Competitors Profiled
- 11
IOL Categories Forecasted
- 8
Geographic and Economic Breakouts
2024 IOL Market Report: Global Analysis for 2023 to 2029, March, 2024
The “2024 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 11 categories of IOLs: commodity monofocal, enhanced monofocal/intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, postoperatively adjustable, and phakic IOLs. Additionally, 34 companies are profiled, with discussion of their products, strategic market position, background, and outlook.
Latest Industry News & Trends
1/17/2025
BreakingDealsGlaucomaRetina
Bausch + Lomb Moves to Acquire Whitecap, InflammX to Expand Clinical Pipeline
Bausch + Lomb recently made moves to acquire two companies that it says will strengthen its expanding pipeline and help address unmet needs in ophthalmology. The company announced Jan. 13 that an a...
1/17/2025
BreakingClinical TrialRetina
Dual Inflammasome Inhibiting Implant Shows Positive Phase I/II Results in GA
Inflammasome Therapeutics reported on Jan. 15 positive topline three-month data from a Phase I/II trial of its K8 dual inflammasome inhibiting implant in geographic atrophy (GA). In the study of fi...
1/17/2025
BreakingGene TherapyRetinaStudy
Study Shows Promise for Genetic Base Editing in Stargardt Disease
Researchers from Switzerland’s Institute of Molecular and Clinical Ophthalmology Basel and Beam Therapeutics say they have developed a gene editing therapy that could potentially treat Stargardt di...
1/17/2025
BreakingDry Eye
Tarsus Will Advance Lotilaner Eyelid Gel for Ocular Rosacea
Tarsus Pharmaceuticals, of Irvine, California, announced Jan. 13 that it would advance TP-04, an ophthalmic gel formulation of lotilaner, targeting ocular rosacea. Tarsus, maker of Xdemvy eye drops...
1/17/2025
AIBreakingDealsFundingRetina
Bausch + Lomb to Collaborate with Character Bio, City Therapeutics in AMD, GA
Bausch + Lomb recently made deals to collaborate with two companies that it says will bolster its expanding pipeline and help address unmet needs in ophthalmology. Character Biosciences reported on...
1/17/2025
BreakingEuropeIOL
Bausch + Lomb Launches EnVista Aspire Monofocal-Plus IOLs in Europe
On Jan. 13, Bausch + Lomb announced the launch of its enVista Aspire intermediate-optimized monofocal and toric intraocular lenses, often referred to as monofocal-plus IOLs, in the EU. The IOLs lau...
1/17/2025
BiosimilarsBreakingDealsEuropeRetina
Teva Signs Deal to Commercialize Formycon’s Aflibercept Biosimilar Candidate in Israel and Most of Europe
Israel’s Teva Pharmaceuticals announced Jan. 13 that it had entered into a collaboration with German companies Klinge Biopharma and Formycon for the semi-exclusive commercialization of FYB203, Form...
1/10/2025
BreakingClinical TrialRetina
Valo Health Suspends Work on Oral DR Candidate After Phase II Trial Misses Endpoints
Valo Health reported Dec. 31 that OPL-0401, its oral diabetic retinopathy treatment candidate, missed its primary and secondary endpoints of improvement in Diabetic Retinopathy Severity Scale score...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.